IMPORTANT SAFETY INFORMATION

Before taking Sandostatin® LAR Depot:
Tell your doctor if you have a history of heart disease or are taking other medications, including: cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine.

Common side effects: Most patients experience side effects at some time. Some common side effects you may experience include: back pain, fatigue, headache, abdominal pain, nausea, and dizziness.

Other information: Patients with carcinoid tumors and VIPomas should adhere closely to their scheduled return visits for reinjection in order to minimize exacerbation of symptoms.

Please see accompanying full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
With the Sandostatin LAR Depot Co-Pay Assistance Program, eligible patients with the severe diarrhea and flushing associated with carcinoid syndrome pay a $25 maximum co-pay for their Sandostatin LAR Depot prescriptions.

Novartis Pharmaceuticals Corporation will pay the remainder of the co-pay for Sandostatin LAR Depot:

- For commercial patients, up to $9600 per calendar year
- For cash patients, up to $800 per injection and $9600 per calendar year

**YOU'RE ELIGIBLE IF YOU**

- Are at least 18 years of age
- Have been diagnosed with the severe diarrhea and flushing symptoms associated with metastatic carcinoid tumors (carcinoid syndrome)
- Have been prescribed, and receive, an approved dose of Sandostatin LAR Depot
- Live in the United States or Puerto Rico
- Have commercial insurance with medical and/or prescription benefits that cover Sandostatin LAR Depot or are paying in full for your Sandostatin LAR Depot
- Are not on Medicare, Medicaid, or other coverage under any federal or state health care program

**IMPORTANT SAFETY INFORMATION**

**Warnings and Precautions:** Treatment with Sandostatin LAR Depot may affect gallbladder function, sugar metabolism, thyroid and heart function, and nutritional absorption, which may require monitoring by your doctor.

Please see additional Important Safety Information and accompanying full Prescribing Information.